Table 3.

Multiple analyses of TE with delayed entry at day 29 (N = 1594)

	N	TE-specific HRa	95% CI	P
Age groups
1.0-9.9 y	1116	1.00 [ref.]
10.0-17.9 y	274	4.9	3.1-7.8	<.0001
18.0-45.9 y	204	6.1	3.7-10.1	<.0001
Sex
Female	715	1.00 [ref.]
Male	879	1.3	0.9-2.0	.1
BMI
>−2SD to <+2SD	79	1.00 [ref.]
≤−2SD	1412	1.4	0.6-3.2	.5
≥+2SD	103	0.8	0.4-1.5	.4
WBC
<100 × 109/L	1396	1.00 [ref.]
≥100 × 109/L	198	1.0	0.5-2.1	>.9
Immunophenotype
BCP	1361	1.00 [ref.]
T-cell	233	1.3	0.4-4.1	.7
CNS status
CNS1	1397	1.00 [ref.]
CNS2/CNS3	197	0.9	0.4-1.6	.6
Mediastinal mass
No	1468	1.00 [ref.]
Yes	126	2.1	1.0-4.3	.04
Enlarged lymph nodes ≥3 cm
No	1480	1.00 [ref.]
Yes	114	1.3	0.7-2.4	.4
Palpable splenomegaly
No	1351	1.00 [ref.]
Yes	243	1.3	0.8-2.0	.3
Induction
Dexamethasone	323	1.00 [ref.]
Prednisolone	1271	1.4	0.4-4.4	.6
Antithrombotic prophylaxis
No	1555	1.00 [ref.]
Yes	39	0.8	0.3-1.9	.6
MRD day 29
<0.001	1095	1.00 [ref.]
≥0.001 to <0.05	425	1.1	0.6-2.0	.7
≥0.05	74	2.3	0.7-7.0	.2
Treatment group day 29
SR	741	1.00 [ref.]
IR	611	0.9	0.5-1.6	.8
HR/HR-SCT	242	0.5	0.2-1.4	.2

ref., reference.